KURA at a glance
Kura Oncology, Inc. (KURA, SEC CIK 1422143) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Kura Oncology, Inc. (KURA) shares worth $389.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Powl Brian T. on November 19, 2026 of 448 shares at $7.27 per share.
- In the last 90 days, KURA insiders reported 5 open-market purchases ($4.2M) and 19 open-market sales ($1.9M) on Form 4, a net purchase of $2.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $67.5M
- +25.2% vs prior year
- Insiders · 90 days
- 5 buys · 19 sells
- Net +$2.3M
- 13F holders
- 27 funds
- $389.9M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $22.8M, versus $20.8M collaboration revenue last year, with $13.9M KOMZIFTI product revenue
- Collaboration revenue $8.9M, down $11.8M year over year from $20.8M
- R&D expenses $66.9M, down from $67.9M, while SG&A declined to $30.2M from $32.8M
- Cash, cash equivalents and short-term investments $492.1M at September 30, 2026, sufficient to fund operations into 2028
- Net cash used in operating activities $202.8M, up from $181.3M, while ATM proceeds totaled $31.5M
- Outlook: R&D and SG&A expected to increase, with additional financing required and Phase 3 topline results anticipated in 2028
Risk Factors
- Newly added commercialization risk: limited experience marketing KOMZIFTI, triggered by its first commercial launch as the company’s first approved product
- Most materially updated regulatory risk: FDA post-approval commitments include pediatric, long-term safety, renal/hepatic impairment, drug-interaction and companion-diagnostic studies
- New compliance exposure: healthcare fraud and abuse laws, including Anti-Kickback Statute, False Claims Act and Sunshine Act requirements
- Near-term market risk: KOMZIFTI competes with FDA-approved REVUFORJ and established AML therapies
- Financial risk: continued losses and potential need for substantial additional capital, creating dilution or operating restrictions
AI summary of the KURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Corporate update accompanies the earnings release
Item EX-99.1: Item EX-99.1
- KOMZIFTI revenue $13.9M, up 53% sequentially, with new patient starts up 30% and prescriptions up 65%
- Majority share of new patient starts supports commercial momentum in R/R NPM1-mutated AML
Item 8.01: Other Events
- Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus
- Kura invested $4.3M and retains approximately 49.2% ownership, preserving substantial economic exposure without majority control
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jennifer Fulk appointed CFO, principal financial officer and principal accounting officer effective September 8, 2026
- Replaces Troy E. Wilson as principal financial officer and Thomas Doyle as principal accounting officer
AI summaries of KURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KURA
Don't miss the next KURA filing
- Alerts as it files. A push when KURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KURA, by share count.
- Ask anything. An AI agent that reads every KURA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Powl Brian T. | Sell | Nov 19, 2026 | 448 | $7.27 |
| Powl Brian T. | Sell | Nov 17, 2026 | 15,254 | $7.45 |
| FORD KATHLEEN | Sell | Nov 17, 2026 | 3,668 | $7.46 |
| Leoni Mollie | Sell | Nov 17, 2026 | 22,241 | $7.45 |
| FORD KATHLEEN | Sell | Nov 16, 2026 | 7,042 | $7.44 |
| Powl Brian T. | Sell | Nov 16, 2026 | 9,196 | $7.44 |
| Leoni Mollie | Sell | Nov 16, 2026 | 19,009 | $7.44 |
| WILSON TROY EDWARD | Buy | Nov 16, 2026 | 101,119 | $7.42 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $53.9M | $67.5M |
| Operating Income | -$165.8M | -$193.2M | -$303.6M |
| Net Income | -$152.6M | -$174.0M | -$278.7M |
| Op. Margin | - | -358.5% | -449.9% |
| Net Margin | - | -322.9% | -412.9% |
| Balance Sheet | |||
| Total Assets | - | $760.2M | $738.4M |
| Equity | - | $413.6M | $174.1M |
| ROE | - | -42.1% | -160.0% |
| Per Share | |||
| EPS | $-2.08 | $-2.02 | $-3.18 |
| Cash Flow | |||
| Operating CF | - | $134.3M | -$64.1M |
| CapEx | - | $472K | $6.6M |
Source: XBRL data in Kura Oncology, Inc. (KURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $389.9M |
| Q2 2026 | 27 | $389.6M |
| Q1 2026 | 27 | $263.7M |
| Q4 2025 | 24 | $356.7M |
| Q3 2025 | 25 | $293.5M |
| Q2 2025 | 26 | $172.3M |
| Q1 2025 | 23 | $132.2M |
| Q4 2024 | 19 | $155.3M |
- BlackRock+1.25M (+12%)
- Two Sigma Investments+696.8K (+416%)
- AQR Capital Management+562.2K (+18%)
- Citadel Advisors LLC+352.0K (+107%)
- Renaissance Technologies LLC+341.5K (+21%)
- State Street Corp−620.3K (-12%)
- Dimensional Fund Advisors−487.9K (-42%)
- Millennium Management−352.9K (-50%)
- Goldman Sachs Group−281.8K (-12%)
- Morgan Stanley−203.1K (-18%)
- FMR LLC (Fidelity)−363.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KURA SEC filings: frequently asked questions
Are KURA insiders buying or selling?
In the last 90 days, Kura Oncology, Inc. (KURA) officers, directors and 10% owners reported 5 open-market purchases worth $4.2 million by 1 insider and 19 open-market sales worth $1.9 million by 6 insiders on Form 4, a net purchase of $2.3 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KURA stock?
As of September 30, 2026, the largest Kura Oncology, Inc. (KURA) holders among the 13F filers tracked by SignalX were BlackRock ($125.9 million), State Street Corp ($50.4 million), Vanguard Capital Management LLC ($41.8 million), AQR Capital Management ($39.5 million), Renaissance Technologies LLC ($21.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KURA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18. The figures come from the XBRL data in the 10-K.
What did KURA report in its latest 8-K?
Kura Oncology, Inc. (KURA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.
What are the latest KURA SEC filings?
Kura Oncology, Inc. (KURA) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.
What is KURA's SEC CIK number?
Kura Oncology, Inc. (KURA)'s SEC Central Index Key (CIK) is 1422143. EDGAR lists every KURA filing under that number.
Ask anything about KURA
The research agent reads KURA's filings, financials, insider trades and 13F holders, then answers with sources.